p53 mediates loss of hematopoietic stem cell function and lymphopenia in Mysm1 deficiency

Blood

Volumn 125, Issue 15, 2015, Pages 2344-2348

  Belle, Jad I ^a,b   Langlais, David ^a,b   Petrov, Jessica C ^a,b   Pardo, Mercedes ^c   Jones, Russell G ^a,d   Gros, Philippe ^a,b,d   Nijnik, Anastasia ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; MYSM1 PROTEIN, MOUSE; PROTEINASE;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL FUNCTION; CELLULAR STRESS RESPONSE; FLOW CYTOMETRY; GENE INTERACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; LYMPHOCYTOPENIA; LYMPHOID PROGENITOR CELL; LYMPHOPOIESIS; MOUSE; MYELOID PROGENITOR CELL; MYSM1 DEFICIENCY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; GENE DELETION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; ENDOPEPTIDASES; GENE DELETION; HEMATOPOIETIC STEM CELLS; LYMPHOPENIA; LYMPHOPOIESIS; MICE; MICE, KNOCKOUT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927663729     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-574111     Document Type: Article

References (25)

1. Zhu P, Zhou W, Wang J, et al. A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell. 2007;27(4):609-621.
2. Jiang XX, Nguyen Q, Chou Y, et al. Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity. 2011;35(6):883-896.
3. Nijnik A, Clare S, Hale C, et al Sanger Institute Microarray Facility; Sanger Mouse Genetics Project. The critical role of histone H2A-deubiquitinase Mysm1 in hematopoiesis and lymphocyte differentiation. Blood. 2012;119(6):1370-1379.
4. Nandakumar V, Chou Y, Zang L, Huang XF, Chen SY. Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1. Proc Natl Acad Sci USA. 2013;110(41):E3927-E3936.
5. Alsultan A, Shamseldin HE, Osman ME, Aljabri M, Alkuraya FS. MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts. Blood. 2013;122(23):3844-3845.
6. Wang T, Nandakumar V, Jiang XX, et al. The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood. 2013; 122(16):2812-2822.
7. Won H, Nandakumar V, Yates P, et al. Epigenetic control of dendritic cell development and fate determination of common myeloid progenitor by Mysm1. Blood. 2014;124(17):2647-2656.
8. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009;9(10):749-758.
9. Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 2012;120(26):5118-5127.
10. Asai T, Liu Y, Bae N, Nimer SD. The p53 tumor suppressor protein regulates hematopoietic stem cell fate. J Cell Physiol. 2011;226(9):2215-2221.
11. Liu Y, Elf SE, Miyata Y, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4(1):37-48.
12. Dumble M, Moore L, Chambers SM, et al. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood. 2007;109(4):1736-1742.
13. Mohrin M, Bourke E, Alexander D, et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell. 2010;7(2):174-185.
14. Blanpain C, Mohrin M, Sotiropoulou PA, Passegué E. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell. 2011;8(1):16-29.
15. Abbas HA, Maccio DR, Coskun S, et al. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell. 2010;7(5):606-617.
16. Milyavsky M, Gan OI, Trottier M, et al. A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell. 2010;7(2):186-197.
17. Wang J, Sun Q, Morita Y, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell. 2012;148(5):1001-1014.
18. Swaminathan S, Duy C, Müschen M. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint. Trends Immunol. 2014;35(3):131-137.
19. Ceccaldi R, Parmar K, Mouly E, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36-49.
20. Freie B, Li X, Ciccone SL, et al. Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood. 2003;102(12):4146-4152.
21. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med. 2010;16(1):59-66.
22. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117(9):2567-2576.
23. Ito E, Konno Y, Toki T, Terui K. Molecular pathogenesis in Diamond-Blackfan anemia. Int J Hematol. 2010;92(3):413-418.
24. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
25. Ochsenbein AF. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 2002;9(12):1043-1055.